Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration ...
Novartis NVS announced positive top-line results from the late-stage STEER study on experimental candidate intrathecal ...
Move means small-cap won't receive an expected payout in the first quarter, creating a cash overhang Sangamo Therapeutics Inc.'s stock tumbled 53% Tuesday to put it on track for its second-biggest one ...
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...
Ractigen Therapeutics proudly announces that its Founder and CEO, Dr. Long-Cheng Li, has been honored with the 2024 Life Science Ice Breaking Award. This award, established by Mr. Cai Lei, a prominent ...
Iovance Biotherapeutics and Adaptimmune brought first-of-their-kind cell therapy cancer treatments to market. Others had to ...
The newly approved medicines in 2024 from Massachusetts companies range from a schizophrenia drug to a gene therapy for ...
The results from the Phase III STEER study add to the clinical data and emerging real-world evidence for the use of one-time ...
The FDA approved an injectable version of Opdivo, a cancer drug by Bristol Myers Squibb. Axsome plans to seek approval for ...
IT has been a truly wonderful year for medicine with pioneering innovative research leading to numerous life-saving breakthroughs that will ...
uniquely designed to replace the function of the missing or defective SMN1 gene.” Assessing the therapy’s efficacy and safety using the Revised Upper Limb Module (RULM) scale were the secondary ...
Sangamo Therapeutics Inc. fell as much as 67% in extended trading after Pfizer Inc. ended its partnership to develop a new ...